ライフサイエンスコーパス: hematopoietic stem cell

1 tissues, and autologous fetal liver-derived hematopoietic stem cells.

2 ogenitors (SEPs) are derived from short-term hematopoietic stem cells.

3 n in committed CD71+ progenitors rather than hematopoietic stem cells.

4 transcriptional priming skews in uncommitted hematopoietic stem cells.

5 ntaining self-renewal and differentiation of hematopoietic stem cells.

6 tion of proreparatory CD150(+)CD48(-)CCR2(+) hematopoietic stem cells.

7 s in patient and donor is indeed required in hematopoietic stem cell and solid-organ transplantation,

8 is disrupted profoundly, with a reduction of hematopoietic stem cells and common lymphoid progenitors

9 which in turn enhances the proliferation of hematopoietic stem cells and decreases hematopoietic pro

10 ransfer of PBMCs or the cotransplantation of hematopoietic stem cells and human thymic tissue (human

11 of the bone marrow that caused depletion of hematopoietic stem cells and impaired proper regeneratio

12 gulated UPR signaling, which often occurs in hematopoietic stem cells and leukemia, defines the degre

13 2 leads to impaired engraftment of long-term hematopoietic stem cells and loss of competitive HSPC re

14 ld mice reduced the number of myeloid-biased hematopoietic stem cells and mature myeloid cells to lev

15 on early during hematopoiesis, in subsets of hematopoietic stem cells and multipotent progenitor popu

16 ctor-beta (TGFbeta) were dysregulated in SDS hematopoietic stem cells and multipotent progenitors, bu

17 ed proliferation of long-term and short-term hematopoietic stem cells and myeloid progenitor cells.

18 for the long-term encoding of ncAAs in human hematopoietic stem cells and reconstitution of this gene

19 matopoiesis is maintained throughout life by hematopoietic stem cells and requires a controlled balan

20 ntigen 4 (CTLA-4) on CML-LSCs but not normal hematopoietic stem cells and this enabled us to specific

21 matopoiesis, provide bounds on the number of hematopoietic stem cells, and quantify the fitness advan

22 the aortic microenvironment, where the first hematopoietic stem cells are generated during developmen

23 w, CSF1R-FRed was absent in lineage-negative hematopoietic stem cells, arguing against a direct role

24 tential (CHIP) refers to clonal expansion of hematopoietic stem cells attributable to acquired leukem

25 that is absent or hardly expressed on normal hematopoietic stem cells, but highly expressed on the su

26 The current paradigm that a single long-term hematopoietic stem cell can regenerate all components of

27 mproving the competitive fitness of specific hematopoietic stem cell clones.

28 lements could have occurred in the patient's hematopoietic stem cells despite the defects in homologo

29 Hematopoietic stem cells develop in a specialized niche

30 mic, epigenetic, and proteomic regulation of hematopoietic stem cell differentiation and the inductio

31 show that Grasp55 deficiency does not affect hematopoietic stem cell differentiation, engraftment, or

32 syndromes (MDS) are a heterogeneous group of hematopoietic stem cell diseases characterized by dyspla

33 a study of young adults chosen as unrelated hematopoietic stem cell donors for patients with hematol

34 Here, we developed a proof-of-concept for hematopoietic stem cell-engineered iNKT (HSC-iNKT) cell

35 m a complete block of differentiation of the hematopoietic stem cell, even a slight skewing of the fr

36 gested that HMGB1 may be required to prevent hematopoietic stem cell exhaustion to ensure immune home

37 severely short telomeres, often resulting in hematopoietic stem cell failure in the most severe cases

38 er-initiating cells that compete with normal hematopoietic stem cells for the bone marrow niche.

39 n in humanized mice reconstituted with human hematopoietic stem cells from donors homozygous for a fu

40 ic leukemia and underwent transplantation of hematopoietic stem cells from his human leukocyte antige

41 ic leukemia and underwent transplantation of hematopoietic stem cells from his human leukocyte antige

42 ifically in the blood system does not impair hematopoietic stem cell function or induce overt patholo

43 1 nor Suv39h2 individually had any effect on hematopoietic stem cell function or the development of m

44 hanges associated with aging such as reduced hematopoietic stem cell function, thymic involution and

45 ng of various factors interacting to control hematopoietic stem cell generation, both in time and spa

46 tic cells, acts as an essential regulator of hematopoietic stem cell generation, survival and functio

47 Hematopoietic stem cell (HSC) attrition is considered th

48 rnative polyadenylation (APA) in controlling hematopoietic stem cell (HSC) behavior in vivo, and the

49 rinsic biases in the activity of fetal liver hematopoietic stem cell (HSC) clones and to uncover a pr

50 ed fitness and increased myeloid bias of the hematopoietic stem cell (HSC) compartment, causing incre

51 alterations, particularly in the control of hematopoietic stem cell (HSC) differentiation, remains p

52 As a clonal hematopoietic stem cell (HSC) disorder, PV is a neoplasm

53 ate harmful inflammatory reactions and cause hematopoietic stem cell (HSC) exhaustion; therefore, IFN

54 We have identified that hematopoietic stem cell (HSC) fitness response to stress

55 nment have emerged as critical regulators of hematopoietic stem cell (HSC) function during diverse pr

56 , including increased inflammation, impaired hematopoietic stem cell (HSC) function, and increased in

57 Hematopoietic stem cell (HSC) gene therapy is being eval

58 Hematopoietic stem cell (HSC) homeostasis is controlled

59 lthough both NKAP and HDAC3 are critical for hematopoietic stem cell (HSC) maintenance and survival,

60 gh bone marrow niche cells are essential for hematopoietic stem cell (HSC) maintenance, their interac

61 timulating bone formation and regulating the hematopoietic stem cell (HSC) niche.

62 ls (MSPCs) are a critical constituent of the hematopoietic stem cell (HSC) niche.

63 Hematopoietic stem cell (HSC) ontogeny is accompanied by

64 nce is a fundamental property that maintains hematopoietic stem cell (HSC) potency throughout life.

65 (miR-146a), increased inflammation, impaired hematopoietic stem cell (HSC) quiescence, and a poor pro

66 A greater understanding of hematopoietic stem cell (HSC) regulation is required for

67 ly, appeared as one of the key regulators of hematopoietic stem cell (HSC) self-renewal and a potenti

68 The balance of hematopoietic stem cell (HSC) self-renewal and different

69 ronic myeloid leukemia (CML) originates in a hematopoietic stem cell (HSC) transformed by the breakpo

70 Hematopoietic stem cell (HSC) transplantation (HSCT) is

71 toxicity and enhanced specificity for robust hematopoietic stem cell (HSC) transplantation and engraf

72 lectin is a key component of the bone marrow hematopoietic stem cell (HSC) vascular niche regulating

73 oliferation are separate functions in normal hematopoietic stem cells (HSC) in steady-state condition

74 Hematopoietic stem cells (HSC) self-renew to sustain ste

75 In young Hopx(-/-) mice, the hematopoietic stem cells (HSC) showed decreased reconsti

76 The limited number of hematopoietic stem cells (HSC) within a single unit of h

77 he JAK2 mutation in all rather than in a few hematopoietic stem cells (HSC), such as in human "early-

78 lentiviral transduction for both T-cell and hematopoietic stem-cell (HSC) targets by greater than tw

79 s from Hoxa(neg/low) Kit(+)CD41(+)CD16/32(+) hematopoietic-stem-cell (HSC)-independent erythro-myeloi

80 ses the frequency of serially transplantable hematopoietic stem cells (HSCs) 6-fold.

81 -CreER enables permanent genetic labeling of hematopoietic stem cells (HSCs) and distinguishes HSC-de

82 exert both positive and negative effects on hematopoietic stem cells (HSCs) and hematopoiesis.

83 cing in immunodeficient mice receiving human hematopoietic stem cells (HSCs) and human thymus grafts.

84 tone H3K27 acetylation of loci important for hematopoietic stem cells (HSCs) and leukemia, such as Ho

85 ion of multipotent hematopoietic cells, i.e. hematopoietic stem cells (HSCs) and multipotent progenit

86 ia (AML) is an aggressive clonal disorder of hematopoietic stem cells (HSCs) and primitive progenitor

87 Cross-talk between hematopoietic stem cells (HSCs) and the HSC niche is lik

88 Human umbilical cord blood (hUCB)-derived hematopoietic stem cells (HSCs) are an important source

89 Hematopoietic stem cells (HSCs) are functionally and gen

90 Hematopoietic stem cells (HSCs) are generated from speci

91 Hematopoietic stem cells (HSCs) are maintained in a peri

92 Hematopoietic stem cells (HSCs) are regulated by signals

93 Small numbers of hematopoietic stem cells (HSCs) balance self-renewal and

94 Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clin

95 multipotent and self-renewing capabilities, hematopoietic stem cells (HSCs) can maintain hematopoies

96 lthough cytokine-mediated expansion of human hematopoietic stem cells (HSCs) can result in high yield

97 The metabolic requirements of hematopoietic stem cells (HSCs) change with their cell c

98 Hematopoietic stem cells (HSCs) develop from the hemogen

99 differentiation, but limits self-renewal of hematopoietic stem cells (HSCs) during aging and inflamm

100 We have used this approach to show that hematopoietic stem cells (HSCs) exhibit an unusually low

101 Hematopoietic stem cells (HSCs) first emerge in the embr

102 NOD/SCID/IL2Rgammanull (NSG) mice with human hematopoietic stem cells (HSCs) following the transducti

103 n points balancing persistence or culling of hematopoietic stem cells (HSCs) for lifelong blood produ

104 The generation of hematopoietic stem cells (HSCs) from embryonic endotheli

105 Mobilization of hematopoietic stem cells (HSCs) has become the preferred

106 Fetal and adult hematopoietic stem cells (HSCs) have distinct proliferat

107 Hematopoietic stem cells (HSCs) have the capacity for se

108 l biologists have been yearning to visualize hematopoietic stem cells (HSCs) in live animals since Ki

109 mmatory diseases, but it remains unclear how hematopoietic stem cells (HSCs) in the bone marrow (BM)

110 The exact localization of hematopoietic stem cells (HSCs) in their native bone mar

111 standing how granulocytes differentiate from hematopoietic stem cells (HSCs) into mature effectors re

112 Targeted gene editing in hematopoietic stem cells (HSCs) is a promising treatment

113 Expansion of human hematopoietic stem cells (HSCs) is a rapidly advancing f

114 Cellular metabolism in hematopoietic stem cells (HSCs) is an area of intense re

115 t progenitor (MPP) compartment downstream of hematopoietic stem cells (HSCs) is commonly hijacked in

116 The proliferative activity of aging hematopoietic stem cells (HSCs) is controversially discu

117 The specific cellular physiology of hematopoietic stem cells (HSCs) is underexplored, and th

118 archy in which a small number of multipotent hematopoietic stem cells (HSCs) maintain all blood linea

119 Somatic DNMT3A mutations arise in hematopoietic stem cells (HSCs) many years before malign

120 ceptor subunit alpha (IL-27Ra) expression on hematopoietic stem cells (HSCs) mediates changes in HSCs

121 As humans age, hematopoietic stem cells (HSCs) occasionally acquire mut

122 We tested for CH in a setting where hematopoietic stem cells (HSCs) of the same individual a

123 Hematopoietic stem cells (HSCs) remain quiescent to pres

124 ders, although its application in engrafting hematopoietic stem cells (HSCs) remains unexplored.

125 lly expressed in CMLSCs compared with normal hematopoietic stem cells (HSCs) represent potential ther

126 Hematopoietic stem cells (HSCs) require highly regulated

127 Adult mammalian hematopoietic stem cells (HSCs) reside in the bone marro

128 Hematopoietic stem cells (HSCs) reside in the bone marro

129 Hematopoietic stem cells (HSCs) survive inflammatory str

130 s all derived from a pool of rare long-lived hematopoietic stem cells (HSCs) that are mostly quiescen

131 lar mechanisms governing the transition from hematopoietic stem cells (HSCs) to lineage-committed pro

132 gues propose to overcome this by engineering hematopoietic stem cells (HSCs) to provide a continual s

133 orts relied on transplantation of "barcoded" hematopoietic stem cells (HSCs) to track the contributio

134 Transplantation of hematopoietic stem cells (HSCs) transduced to express CA

135 Hematopoietic stem cells (HSCs) undergo rapid expansion

136 ying mechanisms and interactions of residual hematopoietic stem cells (HSCs) within the leukemic nich

137 How intrinsic changes to the hematopoietic stem cells (HSCs), an altered microenviron

138 tion in mice resulted in a reduced number of hematopoietic stem cells (HSCs), an increased number of

139 otherapy and irradiation cause DNA damage to hematopoietic stem cells (HSCs), leading to HSC depletio

140 Although IKZF2 is expressed in hematopoietic stem cells (HSCs), we found that it is dis

141 ellular matrix for the maintenance of normal hematopoietic stem cells (HSCs), we investigated a possi

142 has proven difficult to generate functional hematopoietic stem cells (HSCs).

143 lemia accelerates the phenotypes of aging in hematopoietic stem cells (HSCs).

144 nce is critical for the maintenance of adult hematopoietic stem cells (HSCs).

145 ma thrombopoietin (TPO) levels and perturbed hematopoietic stem cells (HSCs).

146 opotent progenitor populations downstream of hematopoietic stem cells (HSCs)/multipotent progenitors

147 Lead markers overlap enhancer marks in hematopoietic stem cells (HSCs, P <= 1.0 x 10(-6)).

148 rgt(m1Wjl)/SzJ mice reconstituted with human hematopoietic stem cells (Hu-NSG mice) and infected with

149 scid IL2rgammanull mice engrafted with human hematopoietic stem cells (hu-SRC-SCID) are susceptible t

150 e bone marrow, where they differentiate from hematopoietic stem cells in a process called granulopoie

151 Mutations were found in more than half the hematopoietic stem cells, including peripheral-blood mye

152 eration and differentiation of primary human hematopoietic stem cells into mature granulocytes, highl

153 ia-associated somatic mutations by 1 or more hematopoietic stem cells is inevitable with advancing ag

154 lk sac and fetal liver as well as definitive hematopoietic stem cells located within the bone marrow

155 ystem led to a 73-fold increase in long-term hematopoietic stem cell (LT-HSC) frequency, as demonstra

156 em, rare self-renewing multipotent long-term hematopoietic stem cells (LT-HSCs) are responsible for t

157 Gene correction in human long-term hematopoietic stem cells (LT-HSCs) could be an effective

158 e how specialized endothelial cells regulate hematopoietic stem cell maintenance and how hematopoieti

159 al cells serve as critical components of the hematopoietic stem cell niche and are thought to protect

160 Physiologic humanization of the hematopoietic stem cell niche proves critical to MDS ste

161 DL1 expression is significantly increased in hematopoietic stem cells of patients with TP53 mutations

162 , which arises from mutations induced within hematopoietic stem cells often through preleukemic fusio

163 lly may also apply to the transplantation of hematopoietic stem cells or solid organ transplants.

164 o valuable therapeutic target cells, such as hematopoietic stem cells or T cells, that are sensitive

165 rovide the influx of maturing cells (such as hematopoietic stem cells) or which started proliferating

166 iased progenitors, followed by precursors of hematopoietic stem cells (pre-HSCs).

167 erived xenografts but does not affect normal hematopoietic stem cells, providing a therapeutic opport

168 d lungs, affected the maturational stages of hematopoietic stem cells, reduced telomerase activity in

169 ation studies revealed that Lsh depletion in hematopoietic stem cells severely reduced B cell numbers

170 elic Gata3 expression in early T lineage and hematopoietic stem cell subsets.

171 from a combination of molecular events in a hematopoietic stem cell that block differentiation and d

172 However, the hematopoietic stem cells that acquire these somatic muta

173 que MUSASHI-2 (MSI2) mRNA binding network in hematopoietic stem cells that changes during transition

174 zumab Ozogamicin with the transplantation of hematopoietic stem cells that have been engineered to ab

175 c progenitors (ETPs) are bone marrow-derived hematopoietic stem cells that remain multipotent and giv

176 of Hopx in maintenance of quiescence of the hematopoietic stem cells through CXCL12 pathway in vivo

177 d fungal infection, as well as assessment of hematopoietic stem cell transduction and engraftment.

178 fe-threatening complication among allogeneic hematopoietic stem cell transplant (alloSCT) recipients.

179 lls and prevent CMV reactivation early after hematopoietic stem cell transplant (HCT).

180 ported outcomes among survivors of pediatric hematopoietic stem cell transplant (HSCT) are understudi

181 t cause of morbidity and mortality following hematopoietic stem cell transplant (HSCT) because of var

182 Allogeneic hematopoietic stem cell transplant (HSCT) can be curativ

183 Therapeutic hematopoietic stem cell transplant (HSCT) during chronic

184 tivated complement is a high-risk feature in hematopoietic stem cell transplant (HSCT) recipients wit

185 ion particularly when complicating allograft hematopoietic stem cell transplant (HSCT).

186 ients who are recipients of a solid organ or hematopoietic stem cell transplant are living longer wit

187 PICU mortality of pediatric cancer and hematopoietic stem cell transplant patients requiring co

188 ,927 PICU admissions of pediatric cancer and hematopoietic stem cell transplant patients, 68 of 70 ev

189 ention of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant patients.

190 a case of cytomegalovirus encephalitis in a hematopoietic stem cell transplant recipient.

191 py or graft versus host disease treatment in hematopoietic stem cell transplant recipients often resu

192 T-cell therapy has been successfully used in hematopoietic stem cell transplant recipients, its exten

193 t morbidity and mortality in solid organ and hematopoietic stem cell transplant recipients.

194 nd it recurs despite resection or allogeneic hematopoietic stem cell transplant.

195 definitive treatment for primary disease is hematopoietic stem cell transplant.

196 5% CI, 11.3-13.2) in those who had undergone hematopoietic stem cell transplant.

197 Autologous hematopoietic stem cell transplantation (AHSCT) with ant

198 stinal microbiota and outcomes in allogeneic hematopoietic stem cell transplantation (allo-HCT) have

199 ts, ie, in long-term survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and

200 success and wider utilization of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is l

201 r obstacle for the wider usage of allogeneic hematopoietic stem cell transplantation (allo-HSCT), whi

202 Allogeneic hematopoietic stem cell transplantation (allo-SCT) offer

203 ctory hematological malignancies, allogeneic hematopoietic stem cell transplantation (alloHSCT) is th

204 Allogeneic hematopoietic stem cell transplantation (alloSCT) is an

205 GVHD) has been observed after haploidentical hematopoietic stem cell transplantation (h-HSCT) with po

206 Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients

207 ecipients of either autologous or allogeneic hematopoietic stem cell transplantation (HSCT) between 1

208 nancies who underwent their first allogeneic hematopoietic stem cell transplantation (HSCT) between J

209 graft composition on clinical outcomes after hematopoietic stem cell transplantation (HSCT) has been

210 Hematopoietic stem cell transplantation (HSCT) improves

211 e potential therapeutic effect of allogeneic hematopoietic stem cell transplantation (HSCT) in autoin

212 Recent findings strongly support hematopoietic stem cell transplantation (HSCT) in patien

213 tal body irradiation (TBI) before allogeneic hematopoietic stem cell transplantation (HSCT) in pediat

214 Hematopoietic stem cell transplantation (HSCT) is a cura

215 Allogeneic hematopoietic stem cell transplantation (HSCT) is a cura

216 disease (GVHD) biology beyond 3 months after hematopoietic stem cell transplantation (HSCT) is comple

217 Presymptomatic hematopoietic stem cell transplantation (HSCT) is the on

218 nborn errors of metabolism (IEM), allogeneic hematopoietic stem cell transplantation (HSCT) is the on

219 gh risk of relapse and mortality in the post-hematopoietic stem cell transplantation (HSCT) period, I

220 atched family donor is available, allogeneic hematopoietic stem cell transplantation (HSCT) should be

221 ry and Sepsis Investigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup

222 a (B-ALL) patients relapsed after allogeneic hematopoietic stem cell transplantation (HSCT) using don

223 Hematopoietic stem cell transplantation (HSCT) was used

224 e current study, we compared the outcomes of hematopoietic stem cell transplantation (HSCT) with TCRa

225 whether treated with conventional therapy or hematopoietic stem cell transplantation (HSCT), and that

226 chemotherapy and in pediatric recipients of hematopoietic stem cell transplantation (HSCT).

227 ut site-directed radiotherapy and allogeneic hematopoietic stem cell transplantation (HSCT).

228 S) is a serious complication post allogeneic hematopoietic stem cell transplantation (HSCT).

229 Currently, the only curative treatment is hematopoietic stem cell transplantation (HSCT).

230 a major cause of morbidity and mortality in hematopoietic stem cell transplantation (HSCT).

231 Whether matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT) can r

232 th consolidation by allogeneic or autologous hematopoietic stem cell transplantation (SCT) and vinbla

233 ed fifty patients (12%) underwent allogeneic hematopoietic stem cell transplantation and 640 (31.0%)

234 Hematopoietic stem cell transplantation and gene therapy

235 r molecular diagnosis, our patient underwent hematopoietic stem cell transplantation and is well 8 ye

236 Hematopoietic stem cell transplantation and NF-kappaB1 p

237 e graft-versus-host disease after allogeneic hematopoietic stem cell transplantation and with new ons

238 ith hematological malignancies or undergoing hematopoietic stem cell transplantation are vulnerable t

239 tients >60 years of age undergoing allogenic hematopoietic stem cell transplantation at our instituti

240 We sought to improve hematopoietic stem cell transplantation by developing a

241 ediatric patients undergoing chemotherapy or hematopoietic stem cell transplantation for hematologica

242 ia, and sensorineural deafness that requires hematopoietic stem cell transplantation for survival.

243 uman myelopoiesis and the curative effect of hematopoietic stem cell transplantation for the hematopo

244 1 remission/functional cure after allogeneic hematopoietic stem cell transplantation from a donor car

245 Because poor B-cell reconstitution after hematopoietic stem cell transplantation has been observe

246 models were critical for the development of hematopoietic stem cell transplantation in alpha- and be

247 s involving bone marrow ablation followed by hematopoietic stem cell transplantation in multiple myel

248 s successful immune reconstitution following hematopoietic stem cell transplantation in NIK deficienc

249 Finally, hematopoietic stem cell transplantation in patients redu

250 Allogeneic hematopoietic stem cell transplantation is curative in m

251 Allogeneic hematopoietic stem cell transplantation is the only avai

252 Hematopoietic stem cell transplantation is the only cura

253 Allogeneic hematopoietic stem cell transplantation is the only pote

254 At present, hematopoietic stem cell transplantation is the therapy o

255 disease or in those with multiple relapses, hematopoietic stem cell transplantation may be considere

256 y, no estimates can be made on the impact of hematopoietic stem cell transplantation on allergy trans

257 ntation, we evaluated 1,974 adult allogeneic hematopoietic stem cell transplantation patients from Be

258 Hematopoietic stem cell transplantation profoundly reduc

259 HLA-haploidentical hematopoietic stem cell transplantation using posttransp

260 The median time for PED development after hematopoietic stem cell transplantation was approximatel

261 ophylaxis of CMV-infection in patients after hematopoietic stem cell transplantation was initiated.

262 patient with Hurler's syndrome treated with hematopoietic stem cell transplantation was referred for

263 confirmed the efficacy of HLA-haploidentical hematopoietic stem cell transplantation with posttranspl

264 Hematopoietic stem cell transplantation would result in

265 (2020) show that hematopoietic stem cell transplantation, an established

266 y, whereas underlying malignancy, allogeneic hematopoietic stem cell transplantation, and neutropenia

267 ors for success are age at diagnosis, age at hematopoietic stem cell transplantation, and the comorbi

268 encies are generally treated with allogeneic hematopoietic stem cell transplantation, but alternative

269 nfectious complications following allogeneic hematopoietic stem cell transplantation, despite novel d

270 or infection associated with solid organ and hematopoietic stem cell transplantation, rapid and accur

271 s for skin cancer associated with allogeneic hematopoietic stem cell transplantation, we evaluated 1,

272 s with seven neutropenic patients undergoing hematopoietic stem cell transplantation, who receive mul

273 s mortality in children following allogeneic hematopoietic stem cell transplantation, with adoptive t

274 transmitting allergen-specific responses via hematopoietic stem cell transplantation.

275 enes that could be corrected with allogeneic hematopoietic stem cell transplantation.

276 hallenges in neutropenia and solid organ and hematopoietic stem cell transplantation.

277 sive body of work in the field of allogeneic hematopoietic stem cell transplantation.

278 uld be potentially corrected with allogeneic hematopoietic stem cell transplantation.

279 ption of adding olanzapine in the setting of hematopoietic stem cell transplantation.

280 HD) remains a major limitation of allogeneic hematopoietic stem cell transplantation.

281 for morbidity and mortality after allogeneic hematopoietic stem cell transplantation.

282 of a patient with AML cured after allogeneic hematopoietic stem cell transplantation.

283 ma, including autologous and even allogeneic hematopoietic stem cell transplantation.

284 therapy followed by autologous or allogeneic hematopoietic stem cell transplantation.

285 mplication of chemotherapy in the setting of hematopoietic stem cell transplantation.

286 eding conventional conditioning regimens for hematopoietic stem cell transplantation.

287 life-threatening complication of allogeneic hematopoietic stem cell transplantation.

288 g results comparable to those of HLA-matched hematopoietic stem cell transplantation.

289 s T-cell reconstitution following allogeneic hematopoietic stem cell transplantation.

290 ory disease that affects patients undergoing hematopoietic stem cell transplantation.

291 lt CMV-seropositive recipients of allogeneic hematopoietic stem cell transplantation.

292 egarding allergic diseases in the context of hematopoietic stem cell transplantation.

293 -associated diarrhea (CDAD) is common during hematopoietic stem-cell transplantation (HSCT) and is as

294 Allogeneic hematopoietic stem-cell transplantation for X-linked sev

295 ollow-up study until 1 year after allogeneic hematopoietic stem-cell transplantation or until 1 year

296 None of the various empirical therapies (hematopoietic stem-cell transplantation, cladribine and

297 or had disease progression after autologous hematopoietic stem-cell transplantation.

298 els developed with human lymphoid tissue and hematopoietic stem cell transplants.

299 ression and selective depletion of recipient hematopoietic stem cells with a CD117-antibody-drug-conj

300 Importantly, CD117-ADC selectively targets hematopoietic stem cells yet does not cause clinically s